Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04248218
Other study ID # Pro0012220
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 12, 2019
Est. completion date June 30, 2022

Study information

Verified date August 2022
Source Children's National Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study, the investigator plans a randomized trial of active rehabilitation and standard care for acute concussion management. The investigator hypothesizes that patients with acute concussions managed with active rehabilitation will have decreased risk of prolonged concussion symptoms.


Description:

Specific Aims: To compare the risk of prolonged concussion symptoms (PCS) between an active rehabilitation and a standard care cohort after an acute concussion. To determine if active rehabilitation compared to routine care reduces the risk of PCS for high-risk patients. This is a prospective randomized control trial of pediatric patients in the emergency department (ED) diagnosed with an acute concussion. Patients 8-18 years old with an acute concussion diagnosis will be eligible. All patients will receive pedometers to monitor their activity levels. If the patient is in the control group the patient will receive standard concussion management per the treating ED physician. Patients in the active rehabilitation group will receive instructions based on the latest CDC concussion management guidelines that specify a symptom-limited progressive return to full activities. This group will be instructed to take at least 10,000 steps a day for five days on their pedometers. One to five days after the ED concussion diagnosis a trained research coordinator will call all subjects to reinforce the management plan. 28 to 32 days post ED concussion diagnosis, research assistants will contact subjects via email or phone call to complete the concussion symptoms inventory.


Recruitment information / eligibility

Status Completed
Enrollment 55
Est. completion date June 30, 2022
Est. primary completion date January 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 8 Years to 18 Years
Eligibility Inclusion Criteria: - Patient diagnosed with an acute concussion within 48 hours - Patient greater than 8 and less than 19 years old Exclusion Criteria: - Major psychiatric diagnosis (bipolar disorder, major depression, does NOT include ADHD/ADD) - Cognitive delay - GCS < 14 - positive findings on head CT - Any patient with intracranial surgery, pathology or instrumentation (e.g. VP shunt, brain tumor etc)

Study Design


Intervention

Behavioral:
Active Rehabilitation Group/Case
If the patient is in the active rehabilitation group, the patient will receive instructions based on the latest CDC concussion management guidelines that specify a symptom-limited progressive return to full activities. This group will be instructed to take at least 10,000 steps a day for five days on their pedometers. In addition, they will also watch a two-minute video by the PI and research team reinforcing the active rehabilitation instructions.

Locations

Country Name City State
United States Children's National Medical Center Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Children's National Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary We will measure and compare the relative risk of prolonged concussion symptoms (PCS) between an active rehabilitation and a standard care cohort one month after an acute concussion. We hypothesize that subjects managed with active rehabilitation post an acute concussion will have a 20% decreased relative risk of PCS compared to those managed with standard care. 28 to 32 days post Emergency Department
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05818644 - Hepatic Artery Stenosis and Thrombosis After Liver Transplantation in Children
Not yet recruiting NCT06018324 - CloudCare in the Treatment of Type 1 Diabetes in Pediatrics
Not yet recruiting NCT04523623 - Pain Control Differences Between Oxycodone and Ibuprofen in Children With Isolated Forearm Injuries N/A
Completed NCT02930850 - Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation N/A
Completed NCT03385681 - Pediatric Pain Management - an Intervention Study N/A
Completed NCT00229671 - Medication Errors and Adverse Drug Events (ADEs) in Ambulatory Pediatrics N/A
Completed NCT04465370 - Pediatric Cardiac Output Monitoring Observational Study
Recruiting NCT04100070 - Intensive Versus Standard One Year Monitoring on Glycaemic Control After Initiating CSII in Children With DT1. DEEP Study N/A
Not yet recruiting NCT06035757 - The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery Phase 4
Completed NCT03369847 - Inhaled Steroids for Pediatric Asthma at Pediatric Emergency Medicine Discharge Phase 4
Completed NCT05474170 - Impact of 2 Resuscitation Sequences on Management of Simulated Pediatric Cardiac Arrest N/A
Recruiting NCT05230004 - Innovative Prosthetic Systems for Pediatric Limb Loss to Accommodate Growth N/A
Completed NCT05818215 - Impact of the Qatar 2022 FIFA World Cup on PED Use and Misuse Patterns
Completed NCT06376188 - Improving Breaking Bad News in Pediatrics by Simulated Communication N/A
Completed NCT05731401 - Expressed Beliefs About the Cause of Pain in a Paediatric Population
Completed NCT04589910 - Measuring Thickness of the Normal Diaphragm in Children Via Ultrasound. N/A
Recruiting NCT04252508 - Impact of a Double-reading Animated Film (Child, Parents) in Preoperative on the Anxiety of Children Upon Arrival at the Operating Room N/A
Completed NCT04655378 - Validation of the IgA1 Detection Method With Gradient Glycosylation by Mass Spectrometry as a Potential Marker of Renal Involvement in Pediatric Rheumatoid Purpura
Completed NCT04610918 - Comparing Body Composition Assessment Methods
Completed NCT03964259 - Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia Phase 1